**Recombinant Bifidobacterium longum Carrying Endostatin Protein Alleviates Dextran Sodium Sulfate-Induced Colitis and Colon Cancer in Rats**

Zhiqian Bi¹, Enqing Cui¹, Yingying Yao¹, Xiaoyao Chang¹, Xiaoyang Wang¹, Yuhui Zhang¹, Gen-Xing Xu*², Hongqin Zhuang*² and Zi-Chun Hua¹,²,³,⁴*¹

¹ The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Sciences, Nanjing University, Nanjing, China, ² Changzhou High-Tech Research Institute of Nanjing University, Changzhou, China, ³ Jiangsu Target Pharma Laboratories Inc., Changzhou, China, ⁴ School of Biopharmacy, China Pharmaceutical University, Nanjing, China

**OPEN ACCESS**

**INTRODUCTION**

Inflammatory bowel disease (IBD), including Crohn’s disease (CD), and ulcerative colitis (UC), is characterized by chronic and recurrent mucosal inflammation of the gastrointestinal tract (Molodecky et al., 2012; Flynn and Eisenstein, 2019). Although the incidence of IBD is increasing, its cause remains poorly understood (Kaplan, 2015; Agrawal et al., 2022; Rana et al., 2022).
Accumulating evidence indicated the importance of gut microbiota, whose disorder is a hallmark of IBD (Alkadhi et al., 2014). Clinically, the gut flora of IBD patients differs dramatically from healthy ones. For example, IBD patients exhibited diminished diversity of their gut microbiome, expansion of pro-inflammatory bacteria like Enterobacteriaceae and Fusobacteriaceae, and depletion of anti-inflammatory bacteria such as Firmicutes (Andoh et al., 2011; Ni et al., 2017; Burrello et al., 2018). Moreover, long-standing chronic inflammation and gut microbiota dysregulation promote IBD development into colon cancer. Clinical studies revealed that regaining the balance of intestinal microbial via oral supplementation of probiotic bacteria is a promising way to prevent IBD and CRC (Sanders et al., 2013; Abreu and Peek, 2014).

Bifidobacteria are anaerobic Gram-positive bacteria that belong to the natural inhabitant of the intestine. Their presence in the human gastrointestinal tract is often associated with health benefits, such as treating and preventing gastrointestinal disorders (Kamada et al., 2013; Fouhy et al., 2019), reducing lactose intolerance (Guerreiro et al., 2014), enhancing immune system (Klaenhammer et al., 2012), preventing and reducing colonization of the gastrointestinal tract by Helicobacter pylori (Miki et al., 2007). Bifidobacterium longum, belonging to the Bifidobacterium genus, has become increasingly attractive in pharmaceutical and dairy products due to their safety and efficacy (Gaggia et al., 2011). It appears in the gut shortly after birth and can be detected throughout an individual’s lifespan. When the normal bacterial flora is disturbed, exogenously supplemented B. longum can rapidly colonize the intestinal tract and strengthen gut barrier function (Lewis et al., 2015; Schroeder et al., 2018).

Many studies have shown that orally administration of B. longum could treat CD and UC (Miyauchi et al., 2013; Jang et al., 2018). Recently, it has been shown that B. longum could be used as a biotherapeutic agent for the treatment of colorectal cancer (CRC; Singh et al., 1997; Fahmy et al., 2019; Valadex-Bustos et al., 2019). Additionally, B. longum exhibited a potent tumor-targeting capability. Yazawa et al. (2000) used B. longum as a delivery system for gene therapy on tumor-bearing mice. Our previous study showed that using B. longum as the delivery system could selectively inhibit angiogenesis and hypoxic tumor growth (Hu et al., 2009). Currently, B. longum as a carrier to express protein or polypeptides with specific functions has become a new therapeutic way for cancer.

Angiogenesis is a tightly regulated process by a network of pro- and anti-angiogenic factors (Carmeliet and Jain, 2000; Italiano et al., 2008). Due to their critical role in promoting tumor growth and metastasis, anti-tumor angiogenesis has become an important cancer therapy target (Li and Cozzi, 2010; Hanahan and Weinberg, 2011). Endostatin is a 20 kDa carboxy-terminal fragment of collagen XVIII and has a strong effect on tumor growth inhibition (Perkins et al., 2009). Several researches showed that endostatin exhibited broad-spectrum antitumor activity in many cancers, such as liver cancer, breast cancer, gastric cancer, and CRC (Ma et al., 2004; Chen et al., 2013; Li et al., 2015). To date, recombinant human endostatin (Endostar) has been approved to treat non-small cell lung cancer. Clinically, the combination of endostatin and chemotherapeutic drugs has been regarded as a promising antitumor treatment strategy. In this study, we selected a strain of B. longum as the delivery system for endostatin protein to treat IBD and colitis-associated CRC.

MATERIALS AND METHODS

Cloning and Expression of Endostatin in Bifidobacterium longum

Wild-type B. longum strain ATCC 55813 was preserved in our laboratory and anaerobically cultured at 37°C in MRS medium supplemented with 0.05% (w/v) L-cysteine. Escherichia coli DH5α was purchased from ATCC and cultured in Luria-Bertani medium. pBV222, a shuttle vector, was kindly provided by the Institute of Virology, China College of Preventive Medical Sciences. The Human endostatin gene was synthesized by Nanjing Genscript Biotech Corporation (China) from the human liver cDNA library. The construction of pBV222-Endo has been described previously (Li et al., 2003). The pBV222 and pBV222-Endo plasmids were transformed directly into B. longum strain ATCC 55813 by electroporation using a Bio-Rad Gene Pulser. Transformed B. longum was screened on TYP agar plates containing 0.5M sucrose and 5 mg/mL CM in anaerobic conditions. Recombinant human endostatin was separated by SDS-PAGE and detected by western blotting. Anti-Endostatin antibodies (Oncogene Research Products, San Diego, United States) were used for western blotting analysis, and the specific preparation was performed according to articles previously reported (Li et al., 2003; Xu et al., 2007).

Experimental Animals and Ethics Approval

All C57BL/6J mice were purchased from Shanghai Laboratory of Animal Center (Shanghai, China) and housed in a temperature-controlled sterile room. Animal welfare and experimental procedures strictly followed high standard animal welfare and related ethical regulations approved by Nanjing University Animal Care and Use Committee.

Induction and Treatment of Dextran Sulfate Sodium-Induced Colitis

As shown in Supplementary Figure 1, we designed the following acute colitis experimental protocol. 3.0% (w/v) dextran sulfate sodium (DSS; molecular weight, 36–50 kDa, MP Biomedicals) dissolved in drinking water was administered ad libitum for seven consecutive days. All mice were randomly divided into the following groups [n = 6–8 for each group]: (1) Control group, in which mice only received tap water without DSS; (2) Model group, in which mice received 3% DSS by drinking water for 7 days, and orally administered daily with 5% glucose in 0.9% NaCl; (3) B. longum group, in which mice were induced colitis by 3% DSS and orally administered daily with WT B. longum; and (4) B. longum-Endo group, in which mice were induced colitis by 3% DSS and orally administered daily with B. longum-Endo. Before gavage, B. longum and B. longum-Endo were washed three times and resuspended with 5% glucose in
0.9% NaCl. Each mouse was orally administrated with 200 µL (1.5 × 10^10 CFU/kg/mouse) of the above suspension and carried out once daily for 7 days continuously. In the recovery experiment period, mice were fed with 3% DSS for 7 days and then changed to sterile water for additional 5 days. Oral administration with *B. longum* (1.5 × 10^10 CFU/kg/mouse) or *B. longum-Endo* (1.5 × 10^10 CFU/kg/mouse) was performed once daily for 12 days. The average water and DSS consumption per mouse per day were the same for all groups.

**Evaluation of Disease Activity of Dextran Sulfate Sodium-Induced Colitis**

At the same time, the life status, fecal condition (fecal morphology and occult blood phenomenon), and body weight of mice were assessed every day. The disease activity index (DAI) was determined by scoring changes in body weight, blood in stool, and stool consistency, as described previously. Briefly, we used five grades of weight loss (no loss = 0, 1–5% = 1, 5–10% = 2, 10–15% = 3, >15% = 4), five grades of stool consistency (normal = 0, mild looseness = 1, looseness = 2, diarrhea = 3, bloody stool = 4), and three grades of occult blood condition (negative = 0, positive = 2, bloody stools visible to the naked eye = 4). The combined scores were then divided by three to obtain the final DAI scores.

**Induction and Treatment of Azoxymethane/Dextran Sulfate Sodium-Induced Colorectal Cancer**

The azoxymethane/dextran sulfate sodium (AOM/DSS)-induced CRC model has been described previously (Liang et al., 2013). As shown in Figure 4A, AOM (Sigma-Aldrich, Hamburg, Germany) was administered by intraperitoneal injection at 10.0 mg per kg body weight (mg/kg). After 7 days, mice received 2.0% DSS in autoclaved water for 7 days followed by recovery on sterile water for 14 days. Three DSS cycles were performed. Oral administration with *B. longum* or *B. longum-Endo* was performed for 14 days and stopped for 7 days in total. The grouping was the same as described in DSS-induced colitis. To better monitor disease progress, we dissected two mice per group randomly every month. All mice were dissected 15 weeks after the first injection of AOM.

**Hematoxylin and Eosin Staining and Histological Score**

Formalin-fixed and paraffin-embedded colorectum tissue was cut in 4 µm sections and stained according to the standard protocol of hematoxylin and eosin (H&E) staining assay. The histological score was evaluated as described previously (Vieira et al., 2009). Briefly, we assessed the severity of inflammation (none = 0, mild = 1, moderate = 2, severe = 3), depth of injury (no mucosal injury = 0, mucosal injury = 1, mucosa and submucosal injury = 2, injury across the intestinal wall = 3), and inflammatory cell infiltration (no or very few inflammatory cells in the lamina propria of the mucosa = 0, more inflammatory cells in the lamina propria of the mucosa = 1, inflammatory cells spread to the submucosa = 2, exudation of inflammatory cells throughout the layer = 3). The combined scores were the colorectal histology score with a total scoring range of 0–9 per mouse.

**RNA Extraction and Quantitative Real-Time PCR**

According to the manufacturer’s instructions, the total RNA of colonic tissue was extracted using Trizol reagent (Vazyme, Nanjing, China). The RNA concentration and quality were determined using a microplate reader for each sample by the 260/280 nm ratio. RNA was reversely transcribed into cDNA using a ReverTra Ace™ qPCR RT Kit (TOYOBO, Japan) according to the manufacturer’s instructions. Quantitative real-time PCR (qRT-PCR) was performed using an AceQ™ qPCR SYBR Green Master Mix (Vazyme, Nanjing, China) and real-time PCR amplification system (Thermo Fisher Scientific, Waltham, MA, United States). The primer sequences were listed in **Supplementary Table 1**. Each qRT-PCR reaction was repeated at least three times and β-actin was used as an internal control.

**16S rRNA Gene Sequencing**

The fecal samples of per mouse were collected in 1.5 mL tubes and immediately frozen in liquid nitrogen. In this study, the number of animals in “Control” was 6, and other treatment groups were all 8. Before sequencing, we mixed mice fecal samples of two mice per group and then extracted DNA. 16s rRNA gene sequencing was performed as described previously in detail (Caporaso et al., 2011). Briefly, genomic DNA was extracted using a QIAamp DNA Stool Mini Kit (51504, QIAGEN) according to the manufacturer’s instructions. The V3–V4 variable regions of the bacterial 16s rRNA gene were amplified by PCR with specific primers: 338F (5′-ACTCCTACGGGAGGCAGCAG-3′) and 806R (5′-GGACTACHVGGGTWTCTAAT-3′). The PCR condition was as follows: initial denaturation at 94°C for 4 min, followed by 25 cycles of 94°C denaturation for 30 s, 50°C annealing for 45 s, and 72°C extension for 30 s; final extension at 72°C for 5 min. PCR products were cleaned and subsequently sequenced by an Illumina MiSeq PE300 system (OEbiotech Co., Ltd.) according to the standard protocols. The resultant sequences were screened for quality using the QIIME software package (version 1.9.1) and the effective sequences were further clustered into Operational Taxonomic Units (OTUs) of ≥97% similarity. The relative abundance of each OTUs, other taxonomic levels (from phylum to genus), beta-diversity (between-sample dissimilarity), and principal component analysis (PCA) were performed for each sample by using MOTHUR program.

**Functional Annotation and Prediction of Microbiota**

The microbial function was predicted using PICRUSt based on the abundance at the OTU level (Langille et al., 2013). The OTUs were mapped to the gg13.5 database at 97% similarity by QIIME’s command “pick_closed_otus.” Then, OTU abundance was normalized automatically using 16S rRNA gene copy numbers from known bacterial genomes of the Integrated
Microbial Genomes\(^1\) database. The predicted genes and their function were annotated with the Kyoto Encyclopedia of Genes and Genomes (KEGG)\(^2\) database, and the differences between groups were compared using the online platform STAMP\(^3\) (Parks and Beiko, 2010). A two-sided Welch’s \(t\)-test and Benjamini–Hochberg false-discovery rate \((P < 0.05)\) were used in the two-group analysis.

### Statistical Analysis

Experiments were performed at least three times with similar results. The results were presented as the mean ± standard deviation (SD) after the analyses were completed with Graph Pad Prism 8.0 (Graph Pad Software, San Diego, CA, United States). Comparisons between two experimental groups were performed using a two-tailed Student’s \(t\)-tests. For multiple comparisons, data were analyzed using a one-way analysis of variance with a Tukey post-test. For all analyses, \(P < 0.05\) was considered statistically significant.

### RESULTS

#### Cloning and Expression of Endostatin in *Bifidobacterium longum*

The whole endostatin gene of 560 bp was amplified from cDNA of human placenta and cloned into the pPRPPL-induction vector pBV222 (Figure 1A). The resulting recombinant plasmids pBV222 and pBV222-endostatin were transformed into *Lactococcus lactis* NZ9000, *Lactobacillus acidophilus* LMG P-219043, and *B. longum* ATCC 55813 (B. longum), respectively. After induction at 42°C for 8 h, total cell protein and secreted protein in the culture supernatant were separately extracted. As shown in Figure 1B, the expected 22 kDa protein product was successfully expressed in three recombinant strains. Among these recombinant strains, *B. longum* showed the highest relative expression of endostatin. We confirmed this result using western blotting and immunofluorescence staining. As shown in Figure 1C, the strain *B. longum* expressed a high level of the endostatin protein (designated as *B. longum*-Endo); however, no endostatin band was found in the parent strain harboring the empty vector pBV222 (designated as *B. longum*). Similarly, no fluorescence was observed in the wild-type strain, while the recombinant strain carried an obvious fluorescence signal (Figure 1D). These results suggested that endostatin protein was successfully expressed in *B. longum*. Surprisingly, the newly constructed recombinant strains displayed an accelerated growth rate. As shown in Figure 1E, the OD value of the wild-type strain was only 0.823 at 24 h, while those of the two recombinant strains were 2.07 and 2.07, respectively. We hypothesized that the recombinant strain *B. longum*-Endo has a higher growth rate, which provides the advantage for performing biological functions in vivo.

\(^1\)http://img.jgi.doe.gov/

\(^2\)http://www.kegg.jp/

\(^3\)http://kiwi.cs.dal.ca/Software/STAMP

#### *Bifidobacterium longum* Alleviates Dextran Sulfate Sodium-Induced Acute Inflammatory Bowel Disease in Mice

We firstly established an acute colitis model in the current study by treating mice with 3% DSS. One day after treatment, mice were administered with normal saline (200 μL/per mouse), *B. longum* \([1.5 \times 10^{10}\) colony-forming units (CFU/kg)], or *B. longum*-Endo \([1.5 \times 10^{10}\) CFU/kg]). During this process, body weight, stool consistency, and fecal occult blood were monitored daily, and each mouse's DAI was further scored. As shown in Figure 2A, the body weight in the control group increased gradually, whereas that of all the treatment groups with DSS decreased considerably as time elapsed. Meanwhile, we found that *B. longum* and *B. longum*-Endo significantly slowed down the body weight decrease of mice in the model group. The body weight of mice in the untreated model group decreased to 77% of the starting weight on the seventh day, while that for *B. longum* and *B. longum*-Endo groups were 87.8 and 84.9%, respectively. Moreover, *B. longum* and *B. longum*-Endo groups showed a significantly lower stool consistency score and fecal bleeding index. Their final DAI score was reduced by 42.5 and 31.6% compared with the model mice \((P < 0.0001; \text{Figure 2B})\). When mice were dissected, there were almost no well-formed stools fecal of colonic tissue in the untreated model group, suggesting that the DSS-induced mouse model had a severe colitis symptom (Figure 2C). Correspondingly, colon length of the model group was also significantly shortened (Figure 2D). In contrast, *B. longum* - and *B. longum*-Endo-treated mice exhibited more formed stool as well as an increase in colon length, indicating that the pathological changes induced by DSS were alleviated after treatment. Furthermore, H&E staining of the colonic tissue showed less reduced villus length, disrupted crypt architecture, and fewer signs of inflammation (Figures 2E,F). After administration of *B. longum* or *B. longum*-Endo, no morphological alterations were evident in close examinations of multiple organs including liver, spleen, lung, and kidney (Supplementary Table 2 and Supplementary Figure 2). Altogether, these results indicated that both *B. longum* and *B. longum*-Endo improved DSS-induced acute IBD in mice.

#### *Bifidobacterium longum*-Endo Administration Further Accelerates the Recovery of Dextran Sulfate Sodium-Induced Acute Inflammatory Bowel Disease in Mice

To further investigate the beneficial effects of *B. longum*-Endo on DSS-induced colitis, we performed a recovery experiment of acute colitis. As shown in Figure 3A, the mice were administered 3.0% DSS for 7 days to cause acute epithelial injury, followed by 5 days of normal drinking water to allow for repair. We find that body weight losses were evident in mice treated with DSS; however, mice could regain their body weight after administration with normal drinking water (Supplementary Figure 3A). Compared to the model group, oral administration of *B. longum* or *B. longum*-Endo significantly
decreased inflammation severity, as evidenced by the DAI scores (Supplementary Figure 3B). Surprisingly, the mean DAI score of the *B. longum-Endo* group was only 0.43 on the 12th day, suggesting that inflammation was almost completely recovered. As shown in Figure 3B, mice with *B. longum-Endo* treatment exhibited a better fecal consistency and firmer stool than the *B. longum* group. Pathology scoring of H&E-stained colon tissue sections harvested on the 12th day also indicated that *B. longum-Endo* treatment had a better therapeutic effect (Figure 3C). Myeloperoxidase (MPO) activity can be used as a marker of inflammation. In this study, we found that MPO activity of mice showed a significant increase after DSS administration for 7 days, whereas *B. longum* and *B. longum-Endo* treatment reduced the MPO level in colon tissues. Notably, compared with the untreated model group, the *B. longum-Endo* group showed a lower MPO on the 12th day, whereas
no significant difference was detected in the *B. longum*-treated group (Figure 3D). In addition, the expression levels of ZO-1 and Occludin were significantly decreased in the DSS-induced group, while *B. longum-Endo* treatment effectively alleviated such changes (Figure 3E). Furthermore, real-time RT-PCR analysis was performed to assess the expression of TNF-α, IL-1β, and
IL-6. The results showed that gene expression levels of pro-inflammatory factors were significantly upregulated in the model group. However, on the 12th day following B. longum-Endo treatment, the expression of TNF-α, IL-1β, and IL-6 were significantly downregulated, although not to that of the control (Figure 3F). Overall, oral delivery of the B. longum-Endo showed a robust conclusion on the therapeutic effect of IBD.

**Bifidobacterium longum-Endo Inhibits Azoxymethane/Dextran Sulfate Sodium-Induced Colon Tumorigenesis**

Colorectal cancer is a chronic inflammatory disorder, and various inflammation mediators control its initiation and progression. To further examine whether B. longum-Endo could be used to treat or delay pathological processes of CRC, we performed an AOM/DSS-induced colitis-associated colon cancer mouse model (Figure 4A). As shown in Figure 4B, AOM/DSS treatment significantly decreased body weight of mice, while B. longum-Endo alleviated this change. The body weight of the B. longum-Endo group was increased by approximately 11.08% compared to that of the model group. We dissected two mice per group randomly every month to assess their overall status during the experiment period. Multiple parameters, including body weight, spleen weight, and colon morphology, showed that B. longum-Endo administration alleviated chronic inflammation caused by AOM/DSS treatment. Interestingly, we found that small intestinal length displayed a similar change trend to the colon length (Tables 1–3). On the 12th week, one mouse in the model and B. longum groups developed macroscopic tumor nodules (Figure 4C). All mice were sacrificed 15 weeks later, and we observed that all eight mice of the model and B. longum groups developed grossly visible tumors at the distal colon or rectum. Notably, only three out of the eight mice developed tumors in the B. longum-Endo group. Compared to the wild B. longum therapy, recombinant B. longum-Endo showed a better antitumor effect in vivo. As shown in Figures 4D,E, the colon tumor numbers and tumor size were remarkably lower in B. longum-Endo-treated mice than in B. longum-treated mice (P < 0.05). Furthermore, immunohistochemistry analysis of tumor tissues showed that the disease score of the B. longum-Endo group was significantly lower than that of the model and B. longum groups (Figures 4F,G). Meanwhile, we found that oral B. longum-Endo administration also significantly prolonged the survival rate of mice (Figure 4H). Taken together, these data demonstrated that B. longum-Endo treatment potently suppressed colorectal tumorigenesis.

**Bifidobacterium longum-Endo Improved Intestinal Flora Dysbiosis Caused by Azoxymethane/Dextran Sulfate Sodium**

Accumulating evidence suggests that intestinal microorganisms are associated with the development of CRC. To determine whether B. longum-Endo treatment affected the gut microbiota, we thus performed 16S ribosomal (rRNA) gene sequencing of fecal samples from the AOM/DSS-treated mice. PCA showed a clear separation between the model and B. longum-Endo groups, suggesting that B. longum-Endo intervention did alter the gut microbial composition (Figure 5A). Based on the species profile, we calculated the alpha diversity to estimate gut microbiota community richness and microbial diversity.
As shown in Supplementary Figure 4, the ACE, Chao1, and Shannon’s indexes of alpha diversity increased significantly in the B. longum-Endo group. However, no significant difference in Simpson’s index was found among the four groups. The gut microbiota community distribution and relative abundance of taxa were further analyzed (Figure 5B). We found that the gut microbiota of all mice was dominated by Firmicutes and Bacteroidota, accounting for more than 80% of all bacterial flora. After induction with AOM/DSS, the relative abundance of Firmicutes was significantly increased compared with the control group. Compared with the model group, the relative Bacteroidota abundance in the B. longum-Endo treatment group increased by approximately 27.19%, while the Desulfobacterota abundance decreased by 48.44%. Strikingly, the relative abundance of Actinobacteriota phylum was almost twice higher in the B. longum-Endo group than that in the model group (Figure 5C). In addition, we found that the relative abundance of Verrucomicrobiota was significantly decreased in the model group, while B. longum did not improve Verrucomicrobiota abundance. Next, the changes of genus level in fecal microbiota composition were further analyzed. Here, we focused on the top 30 intestinal microflora, and the results were presented in Figure 5D. Although the individual difference was observed, the main gut microbiota diversity changes showed a consistent trend. AOM/DSS treatment reduced the abundance of beneficial bacteria and increased potential harmful bacteria. As expected, following B. longum and B. longum-Endo treatment, the imbalanced structure of the intestinal flora was improved. As shown in Figure 5E, the abundance of Lactobacillus was 24.6% in the B. longum-Endo group but only 9.29% in the model group. Similarly, Bacteroides and Ileibacterium abundance showed an increasing trend in the B. longum-Endo group. Notably, B. longum-Endo treatment significantly decreased the abundance of Desulfovibrio and Allobaculum, while no significant differences were observed between the model and B. longum groups (Figure 5E). Furthermore, we found that B. longum-Endo decreased the relative abundance of potentially pathogenic genera, such as Desulfovibrio, Helicobacter, Alistipes, and Enterorhabdus (Figure 5F). Compared with the B. longum group, the relative abundance of Desulfovibrio was significantly decreased (P < 0.05) in the B. longum-Endo group, while Parabacteroides and Parasutterella abundance were significantly increased (Figure 5G). Altogether, these results suggested that B. longum-Endo improved the intestinal flora dysbiosis caused by AOM/DSS.

Predictive Functional Profiles of Bacterial Communities

To determine the significant pathways involved in differential bacteria, we used the KEGG pathway database to predict putative functions. Table 4 presented the predicted microbial functions at level 1 of the KEGG pathways. After AOM/DSS treatment, four functional orthologs including cellular processes, organismal systems, environmental information processing, and human diseases were significantly altered. Compared with the model group, the abundance of bacteria involved in metabolism functional ortholog was significantly decreased in the B. longum group. In contrast, the abundance of
TABLE 1 | Organ parameter changes in mice at 4 weeks after AOM injection.

| Group       | Body weight (g) | Liver (g) | Spleen (g) | Kidney (g) | Small intestine length (cm) | Colon length (cm) |
|-------------|-----------------|-----------|------------|------------|-----------------------------|------------------|
| Control-1   | 26.9            | 1.426     | 0.068      | 0.313      | 39                          | 8.59             |
| Control-2   | 27.7            | 1.424     | 0.072      | 0.327      | 37.3                        | 8.13             |
| Model-1     | 24.8            | 1.314     | 0.670      | 0.298      | 33.1                        | 6.2              |
| Model-2     | 25.3            | 1.369     | 0.683      | 0.293      | 35.2                        | 6.36             |
| B. longum-1 | 24.3            | 1.268     | 0.680      | 0.282      | 37.4                        | 7.36             |
| B. longum-2 | 26.0            | 1.386     | 0.702      | 0.494      | 36.2                        | 7.05             |
| B. longum-Endo-1 | 26.7     | 1.410     | 0.721      | 0.320      | 37.2                        | 7.42             |
| B. longum-Endo-2 | 26.0   | 1.420     | 0.705      | 0.312      | 35.5                        | 7.78             |

TABLE 2 | Organ parameter changes in mice at 8 weeks after AOM injection.

| Group       | Body weight (g) | Liver (g) | Spleen (g) | Kidney (g) | Small intestine length (cm) | Colon length (cm) |
|-------------|-----------------|-----------|------------|------------|-----------------------------|------------------|
| Control-1   | 29.8            | 1.582     | 0.775      | 0.334      | 36.6                        | 7.89             |
| Control-2   | 28.2            | 1.531     | 0.705      | 0.327      | 35                          | 8.20             |
| Model-1     | 26.2            | 1.420     | 0.760      | 0.304      | 32.4                        | 7.49             |
| Model-2     | 27.1            | 1.507     | 7.859      | 0.320      | 33.5                        | 7.32             |
| B. longum-1 | 27.1            | 1.480     | 0.786      | 0.325      | 35.7                        | 8.12             |
| B. longum-2 | 29.9            | 1.555     | 0.852      | 0.359      | 36.8                        | 8.31             |
| B. longum-Endo-1 | 27.3   | 1.502     | 0.764      | 0.322      | 34.3                        | 7.74             |
| B. longum-Endo-2 | 30.6   | 1.655     | 0.857      | 0.355      | 33.2                        | 7.26             |

TABLE 3 | Organ parameter changes in mice at 12 weeks after AOM injection.

| Group       | Body weight (g) | Liver (g) | Spleen (g) | Kidney (g) | Small intestine length (cm) | Colon length (cm) |
|-------------|-----------------|-----------|------------|------------|-----------------------------|------------------|
| Control-1   | 31.800          | 1.654     | 0.789      | 0.347      | 35.4                        | 8.49             |
| Control-2   | 33.500          | 1.782     | 0.908      | 0.395      | 35.6                        | 8.10             |
| Model-1     | 26.800          | 1.514     | 0.911      | 0.319      | 30.8                        | 7.82             |
| Model-2     | 27.500          | 1.491     | 0.963      | 0.344      | 32                          | 7.98             |
| B. longum-1 | 27.800          | 1.562     | 0.834      | 0.334      | 33.4                        | 7.74             |
| B. longum-2 | 28.400          | 1.500     | 0.852      | 0.349      | 34.6                        | 7.52             |
| B. longum-Endo-1 | 28.500 | 1.519     | 0.827      | 0.342      | 35                          | 7.49             |
| B. longum-Endo-2 | 29.900 | 1.588     | 0.867      | 0.362      | 32.8                        | 7.21             |

bacteria related to environmental information processing was significantly decreased in the B. longum-Endo group. A heat map reflecting hierarchical clustering of relative bacterial abundances and their associated function orthologs in level 2 and 3 KEGG pathways were presented in Supplementary Figure 5. In level 2 KEGG pathways, intestinal flora with high abundance in the B. longum-Endo group was related to pathways including cancers, endocrine_and_metabolic_disease, folding_sorting_and_degradation, and translation (Supplementary Figure 5A). Furthermore, differential bacteria (P < 0.05, Model vs. B. longum-Endo or Model vs. B. longum) were analyzed based on the third-level KEGG pathways (Supplementary Figure 5B). Compared with the model group, the increased microbiota in the B. longum-Endo group codifies functions in KEGG pathways related to prokaryotic defense system, sulfur relay system, steroid hormone biosynthesis, protein digestion and absorption, CD molecules, small cell lung cancer, systemic lupus erythematosus. Meanwhile, we found that the decreased microbiota in the B. longum-Endo group (P < 0.05) were related to 23 pathways. Among these, significant differential bacteria (B. longum-Endo vs. Model, P < 0.01), such as Desulfovibrio, Helicobacter, and Alistipes, were related to oxidative phosphorylation, renin-angiotensin system and apoptosis pathways. Here, we found that two pathways, namely...
oxidative phosphorylation and lysine biosynthesis, showed significant differences between the *B. longum* group and the *B. longum-Endo* group.

**DISCUSSION**

Probiotics have been increasingly applied in the food and pharmaceutical industry to prevent disease and improve host health. Some studies have demonstrated that oral delivery of specific probiotic strains such as *Bifidobacterium* could improve intestinal immunity and alleviate IBD and CRC. In the current study, we constructed a recombinant strain of *B. longum-Endo*, which expressed a high level of endostatin protein, and demonstrated its ability of anti-inflammation and anti-tumor in animal models for the first time.

*Bifidobacterium* as a therapeutic delivery system has many advantages: (1) *Bifidobacterium* itself has a variety of physiological functions, such as anti-inflammation and anti-tumor effects. (2) *Bifidobacterium* exhibits a strong colonization ability. It appears in the gut shortly after birth and can be detected throughout an individual's lifespan. Compared to the *Lactobacillus*, *Bifidobacterium* is more accessible to be colonized in the gut, which is very suitable for expressing some peptide drugs in the intestinal tract (Drolia et al., 2020; Miranda et al., 2021). (3) Good safety. The body has immune tolerance to *Bifidobacterium* since its long-term colonization in the intestine. Therefore, long-term use will not cause rejection. (4) *Bifidobacterium* displays superior *in vivo* tumor-targeting ability. When genetically engineered *Bifidobacterium* was introduced systemically into tumor-bearing mice, bacteria were found only in the tumors, presumably due to the hypoxic environment required for the growth of these bacteria (Yazawa et al., 2000). Despite the above merits, the research progress on *B. longum* is far from satisfactory. Indeed, the “probiotic-based delivery system” genetic engineering is still in its infancy. As our previous study has successfully constructed recombinant strains *L. lactis-Endo*, *L. acidophilus-Endo*, and *B. longum-Endo*, and the expression of endostatin was the highest in *B. longum*. In this study, we further explored the effect of *B. longum-Endo* on the treatment of IBD in animal models. The results indicated that oral administration of *B. longum-Endo* attenuated DSS-induced acute colitis, as demonstrated by a reduction of colitis indices, intestinal shortening, and histological changes at both macroscopic and microscopic levels. Proinflammatory factors are closely related to intestinal inflammation and clinical symptoms of IBD. TNF-α, a canonical pro-inflammatory cytokine, was found to be upregulated in colon tissue of IBD patients (Murch et al., 1993). In the animal models, including TNBS and DSS-induced colitis, TNF-α was also significantly upregulated (Marini et al., 2003). Herein, we demonstrated that *B. longum-Endo* reduced the level of TNF-α at the inflammation site, and by 12 days after treatment, TNF-α expression returned to the basal level. Early studies implicated that IL-6 is a multifunctional cytokine produced during inflammation; inhibiting the IL-6/STAT3 signaling pathway may be a potential therapeutic target for IBD (Matsumoto et al., 2009). Notably, IL-6 was the most responsive to *B. longum-Endo* in treating colitis, with its expression level changed by 4.6 times after treatment. As a marker of tissue damage and neutrophil infiltration, MPO activity is closely correlated with IBD severity (Zhao et al., 2019). MPO levels are usually upregulated in IBD patients (Ma et al., 2004). In agreement with previous studies, we also detected high levels of MPO in the colon tissue of mice induced by DSS, and *B. longum-Endo* reduced MPO activity significantly. Collectively, recombinant *B. longum-Endo* achieved therapeutic effect without toxic side effects on colitis.

Chronic inflammation, one of the “promoting forces” in the tumor microenvironment, has been suggested to be associated with the initiation, promotion, and progression of tumorigenesis. Recent prospective observational studies suggested that IBD patients displayed an increased prevalence of CRC (Gillen et al., 1994; Derikx et al., 2017; Samadder et al., 2019; Weimers et al., 2021). In this study, we constructed an AOM/DSS mouse model by which chronic inflammation is a major driver of tumorigenesis and promotion. Our data showed that *B. longum-Endo* played a critical role in tumorigenesis and promotion, with evidence that the disease score and tumor formation rate were lower than that of the untreated model group and *B. longum* group. Compared with the wide *B. longum*, recombinant *B. longum-Endo* showed superior anti-tumor efficacy with lower tumor numbers and tumor size, which seems to be well accounted for by the endostatin protein. Endostatin is a 20–28 kDa proteolytic fragment of collagen XVIII with potent antiangiogenic activity (O’Reilly et al., 1997). Recombinant endostatin has been considered as a broad-spectrum anticancer agent because of its endogenous inhibitory effect on angiogenesis, non-toxicity, and synergistic ability with chemotherapy drugs (Boehm et al., 1997; Folkman, 2006; Zhuang and Yuan, 2009). Currently, recombinant endostatin (Endostar) has been approved for the treatment of NSCLC by the State Food and Drug Administration of China, which is expressed and purified in *E. coli* with an additional nine-amino acid sequence (Hu et al., 2014). However, its short half-life and instability limit clinical applications. Great efforts are currently devoted to gene therapy by which endostatin can be delivered and expressed in specific tumor regions *in vivo* (Li et al., 2003; Ma et al., 2004). Jia et al. (2004) reported that endostatin slowed or even stopped tumor growth, but when treatment stopped, tumors began to re-grow rapidly. Pleasingly, we found that *B. longum* as a delivery system to carry endostatin showed long-term safety and efficacy for colon cancer. When administration with *B. longum-Endo* stopped, the primary tumor did not grow, and the mouse’s overall survival rate was also improved. We thus concluded that the combination of *B. longum* and endostatin showed self-amplifying, synergistic anti-inflammation, and anti-tumor effects in CRC.
FIGURE 5 | *B. longum*-Endo improved intestinal flora dysbiosis caused by AOM/DSS. **(A)** Principal components analysis (PCA). **(B)** Overview of relative abundance of microbiota at phylum level in mice. **(C)** The relative abundance changes of Firmicutes, Bacteroidotes, Desulfo bacterotes, Actinobacteria, and Verrucomicrobiota after *B. longum*-Endo treatment. **(D)** Heatmap depicting the relative abundance of bacterial species at genus level for each mouse. **(E)** Relative abundance of representative beneficial bacteria (*Lactobacillus*, *Bacteroides*, *Ileibacterium* *Bifidobacterium*, and *Allobaculum*). **(F)** Relative abundance of representative harmful bacteria (*Desulfovibrio*, *Helicobacter*, *Alistipes*, and *Enterorhabdus*). **(G)** Representative differential microbiota (*B. longum*-Endo group vs. *B. longum* group, *P* < 0.05). *P* < 0.05; **P** < 0.01; ns: not significant.
Increasing evidence has indicated that gut microbiota plays an essential role in maintaining intestinal homeostasis (Marchesi et al., 2016). Dysbiosis of the gut microbiota is closely related to IBD and CRC development (Peterson et al., 2015). For example, decreased beneficial Lactobacillus and increased potential harmful Enterobacteria are closely related to IBD severity and treatment effectiveness (Zhou et al., 2018). Our study revealed that the relative abundance of potentially pathogenic bacteria including Helicobacter, Desulfovibrio, Alistipes, and Enterorhabdus increased in AOM/DSS-induced mice, but decreased after B. longum-Endo treatment. Desulfovibrio is a genus of sulfate-reducing bacteria that is ubiquitous in oligotrophic and eutrophic environments. Overproduction of H₂S by Desulfovibrio in the colon has been implicated in colonic inflammation and cancer (Loubinoux et al., 2002; Carbonero et al., 2012). Compared to the wild B. longum, B. longum-Endo treatment significantly decreased the relative abundance of Desulfovibrio, which may contribute to inhibiting H₂S generation. Notably, Alistipes, one of the top ten most abundant genera associated with human colorectal carcinomas, has been proposed as a potential biomarker for CRC (Moschen et al., 2016). Oral supplementary of recombinant B. longum-Endo heightened colonization of Bifidobacterium in the gut and increased proliferation of Bifidobacterium species. In this study, we found that the relative abundance of intestinal Bifidobacterium was significantly increased only in the B. longum-Endo group. Among the taxa identified, the most notable were the Parabacteroides and Parasutterella in the B. longum-Endo group. Parabacteroides is a core component of the human and mouse gut microbiota and has been correlated with various health outcomes. Administration of Parabacteroides alleviated heparanase-exacerbated acute pancreatitis through reducing neutrophil infiltration (Lei et al., 2021). In accordance with our study, several studies recently reported that Pabacteroides alleviated AOM/DSS-induced inflammation (Koh et al., 2018; Koh et al., 2020). Parasutterella is still a relatively new genus with limited literature. Henneke et al. (2022) reported Parasutterella was associated with obesity and type 2 diabetes, but not with systemic inflammatory markers like IL-6. Interestingly, IL-6 reflects the degree of metabolic inflammation in obesity (Park et al., 2005). In IBS patients, it has been observed that altered Parasutterella is commonly linked with changes in gastrointestinal function (Chen et al., 2018). Our result indicated that B. longum-Endo significantly increased the abundance of Parasutterella in the gut, which might be an attractive candidate for future investigations. In addition to the effects of B. longum-Endo on cancer development inhibition, it is unclear how endostatin protein itself affects microbial differences. Overall, our data indicated that Desulfovibrio, Parabacteroides, and Parasutterella might be important candidates for explaining the relationship between “endostatin” and “gut microbiota.” Nevertheless, future studies are needed to correlate such intestinal microbiota more definitively with recombinant B. longum-Endo.

**CONCLUSION**

In conclusion, we demonstrated that B. longum-Endo alleviated inflammation response by inhibiting the expression of pro-inflammatory factors in DSS-induced colonic inflammation. Moreover, long-term oral administration of B. longum-Endo efficiently inhibited CRC tumorigenesis and improved intestinal flora dysbiosis. Our study suggested that oral administration of recombinant B. longum-Endo strain may be a promising therapeutic strategy for IBD and colitis-associated cancer.

**DATA AVAILABILITY STATEMENT**

The data presented in the study are deposited in the NCBI Sequence Read Archive repository, accession number: PRJNA838451. Raw data is available at this link: https://www.ncbi.nlm.nih.gov/sra/PRJNA838451.
ETHICS STATEMENT

The animal study was reviewed and approved by Nanjing University Animal Care and Use Committee.

AUTHOR CONTRIBUTIONS

HZ, Z-CH, and G-XX designed the outline of the manuscript. HZ revised this manuscript. ZB performed most of the experiments in this study and wrote the manuscript. EC and YY helped with the recombinant strain construction-related experiments. XC, XW, and YZ helped with the experiments using animals. All authors have read and approved the final version of this manuscript.

FUNDING

This study was supported by grants from the Chinese National Natural Sciences Foundation (82130106 and 81773099), the National Key R&D Program of China (2017YFA0506002), and the Jiangsu Province Natural Sciences Foundation (BK201905).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2022.927277/full#supplementary-material

REFERENCES

Abreu, M. T., and Peek, R. M. (2014). Gastrointestinal malignancy and the microbiome. Gut Pathog. 6, 25. doi: 10.1186/1757-4749-6-25
Andoh, A., Imaeda, H., Aomati, T., Inatomi, O., Bamba, S., Sasaki, M., et al. (2011). Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J. Gastroenterol. 46, 479–486. doi: 10.1007/s00535-010-0368-4
Beohm, T., Folkman, J., Browder, T., and O'Reilly, M. S. (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404–407.
Burrello, C., Garavaglia, F., Cribiù, F. M., Ercoli, G., Lopez, G., Troisi, J., et al. (2018). Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. Nat. Commun. 9:5184. doi: 10.1038/s41467-018-07359-8
Carbonero, F., Benediet, A. C., Alizadeh-Ghamsari, A. H., and Gaskins, H. R. (2012). Microbial pathways in colonic sulfur metabolism and links with health and disease. Front. Physiol. 3:488. doi: 10.3389/fphys.2012.00448
Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nat. Rev. Cancer 1, 579–592. doi: 10.1038/75784
Chen, J., Yao, Q., Li, D., Zhang, J., Wang, T., Yu, M., et al. (2013). Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study. BMC Cancer 13:248. doi: 10.1186/1471-2407-13-248
Chen, Y. J., Wu, H., Wu, S. D., Lu, N., Wang, Y. T., Lin, H. N., et al. (2018). Parasutterella, in association with irritable bowel syndrome and intestinal chronic inflammation. J. Gastroenterol. Hepatol. 33, 1844–1852. doi: 10.1111/jgh.14281
Deriks, L. A., Smits, L. J., van Vliet, S., Dekker, E., Aalfs, C. M., van Kouwen, M. C., et al. (2017). Colorectal cancer risk in patients with Lynch syndrome and inflammatory bowel disease study. Clin. Gastroenterol. Hepatol. 15, 454–458. doi: 10.1016/j.cgh.2016.08.005
Dro silky, O., Amalaradjou, M. A. R., Ryan, V., Tenguria, S., Liu, D., Bai, X., et al. (2020). Receptor-targeted engineered probiotics mitigate lethal Listeria infection. Nat. Commun. 11:6344. doi: 10.1038/s41467-020-20200-5
Fahmy, C. A., Gamal-Eldeen, A. M., El-Hussieny, E. A., Rafat, B. M., Mehanna, N. S., Talaat, R. M., et al. (2019). Bifidobacterium longum suppresses murine colorectal cancer through the modulation of oncomiRs and tumor suppressor miRNAs. Nutr. Cancer 71, 688–700. doi: 10.1080/01635581.2019.1577984
Flynn, S., and Eisenstein, S. (2019). Inflammatory bowel disease presentation and diagnosis. Surg. Clin. North Am. 99, 1051–1062.
Folkman, J. (2006). Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp. Cell Res. 312, 594–607. doi: 10.1016/j.yexcr.2005.11.015
Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646–674.
Henneke, L., Schlicht, K., Andreani, N., Hollstein, T., Demetrowitsch, T., Knappe, C., et al. (2022). A dietary carbohydrate-gut Parasutterella-human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes. Gut microbes 14, 2057778. doi: 10.1007/s12602-022-2057778
Hong, N., Ku, S., Yuk, K., Johnston, T. V., and Park, M. S. (2021). Production of biologically active human interleukin-10 by Bifidobacterium bifidum BGN4. Microb. Cell Fact 20:16. doi: 10.1186/s12934-020-01505-5
Hu, B., Kou, L., Li, C., Zhu, L. P., Fan, Y. R., Wu, Z. W., et al. (2009). Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. Cancer Gene Ther. 16, 655–663. doi: 10.1038/cgt.2009.7
Hu, M. M., Hu, Y., Zhang, H. Q., Jia, W. Y., Qian, Z., Yang, Y., et al. (2014). Clinical significance of serum and tumor tissue endostatin evaluation in operable non-small cell lung cancer. Biomed. Rep. 2, 898–904. doi: 10.3892/br.2014.319
Jang, S. E., Jeong, J. J., Kim, J. K., Han, M. J., and Kim, D. H. (2018). Simultaneous amelioration of colitis and liver injury in mice by Parasutterella and differentially released. World J. Gastroenterol. 24(34):8983–8990. doi: 10.3748/wjg.v24.i34.8983
Jia, Y. H., Dong, X. S., and Wang, X. S. (2004). Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice. World J. Gastroenterol. 10, 3361–3364. doi: 10.3748/wjg.v10.i22.3361
Miranda, C., Contente, D., Igrejas, G., Câmara, S. P. A., Dapkevicius, M. L. E., et al. (2021). Role of exposure to lactic acid bacteria from foods of animal origin in human health. Foods 10, 2092. doi: 10.3390/foods10092092

Miyauchi, E., Ogita, T., Miyamoto, J., Kawamoto, S., Morit, A. H., Ohno, H., et al. (2013). Bifidobacterium longum alleviates dextran sulfate sodium-induced colitis by suppressing IL-17A response: involvement of intestinal epithelial costimulatory molecules. PLoS One 8:e79735. doi: 10.1371/journal. pone.0079735

Molodecky, N. A., Soon, I. S. B., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., et al. (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46–54. doi: 10.1053/j.gastro.2011.10.001

Moschen, A. R., Gerner, R., Wang, J., Klepsch, V., Adolph, T. E., Reider, S. J., et al. (2016). Lipocalin 2 protects from inflammation and tumorigenesis associated with gut microbiota alterations. Cell Host Microbe 19, 455–469. doi: 10.1016/j.chom.2016.03.007

Murch, S. H., Braegger, C. P., Walker-Smith, J. A., and MacDonald, T. T. (1993). Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34, 1705–1709. doi: 10.1136/gut.34.12.1705

Ni, J., Chen, T. D., Chen, E. Z., Bittinger, K., Bailey, A., Roggiani, M., et al. (2017). A role for bacterial urease in gut dysbiosis and Crohn’s disease. Sci. Transl. Med. 9:eaah6888. doi: 10.1126/scitranslmed.aaeh6888

O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasis, G., Lane, W. S., et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285.

Park, H. S., Park, J. Y., and Yu, R. (2005). Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res. Clin. Pract. 69, 29–35. doi: 10.1016/j.diabres.2004.11.007

Park, D. H., and Reiko, R. G. (2010). Identifying biologically relevant differences between metagenomic communities. Bioinformatics 26, 715–721. doi: 10.1093/bioinformatics/btp041

Perkins, G. D., Nathani, N., Richter, A. G., Park, D., Syamasundar, M., Helgasava, R., et al. (2009). Type XVIII collagen degradation products in acute lung injury. Crit. Care 13:R52. doi: 10.1186/cc7779

Peterson, C. T., Sharma, V., Elmén, L., and Peterson, S. N. (2015). Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin. Exp. Immunol. 179, 363–377. doi: 10.1111/cei.12474

Rana, N., Privitera, G., Kondolf, H., Bulek, K., Lechuga, S., De Salvo, C., et al. (2022). GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis. Cell 185, 283–298. doi: 10.1016/j.cell.2021.12.024

Samadder, N. J., Valentine, J. F., Guthery, S., Singh, H., Bernstein, C. N., Leighton, J. A., et al. (2019). Family history/associates with increased risk of colorectal cancer in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 9, 1807–1813.

Sanders, M. E., Guarnier, F., Guerrant, R., Holt, P. R., Quigley, E. M., Sartor, R. B., et al. (2013). An update on the use and investigation of probiotics in health and disease. Gut 62, 787–796. doi: 10.1136/gutjnl-2012-302504

Schroeder, B. O., Birchough, G. M. H., Stählin, M., Arike, L., Johannson, M. E. V., Hansson, G. C., et al. (2018). Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host Microbe 23, 27–40. doi: 10.1016/j.chom.2017.11.004

Singh, J., Rivenson, A., Tomita, M., Shimamura, S., Ishibashi, N., and Reddy, B. S. (1997). Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 18, 833–841. doi: 10.1093/carcin/18.4.833

Valadrez-Bustos, N., Escamilla-Silva, E. M., García-Vázquez, F. J., Gallegos-Corona, A. M., Amaya-Ilano, S. L., and Ramos-Gómez, M. (2019). Oral Administration of microencapsulated B. longum BAA-999 and lycopene modulates IGF-1/IGF-1R/IGFBP3 protein expressions in a colorectal murine model. Int. J. Mol. Sci. 20, 4275. doi: 10.3390/ijms20174275

Vieira, A. T., Fagundes, C. T., Alessandri, A. L., Castor, M. G., Guabiraba, R., Vieira, A. T., Fagundes, C. T., Alessandri, A. L., Castor, M. G., Guabiraba, R., et al. (2009). A component of polysaccharide peptidoglycan complex on Helicobacter pylori 1R/IGFBP3 protein expressions in a colorectal murine model. Carcinogenesis 30, 107–112. doi: 10.1093/carcin/bgp010

Vieira, A. T., Fagundes, C. T., Alessandri, A. L., Castor, M. G., Guabiraba, R., Vieira, A. T., Fagundes, C. T., Alessandri, A. L., Castor, M. G., Guabiraba, R., et al. (2009). A component of polysaccharide peptidoglycan complex on Helicobacter pylori 1R/IGFBP3 protein expressions in a colorectal murine model. Carcinogenesis 30, 107–112. doi: 10.1093/carcin/bgp010

W. C., et al. (2013). Sphingosine-1-phosphate links persistent STAT3 activation, therapy. J. Chemother. 27, 238–244. doi: 10.1179/1973947815Y.0000000022

Yang, J., Zhang, Y., Wang, X. Y., Gao, L. F., Liu, H., Guo, C., et al. (2015). Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 22, 105–111. doi: 10.1016/j.cgt.2015.07.030

Yamada, A., Huang, Z., Honda, M., et al. (2015). Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome 3:13. doi: 10.1186/s40168-015-0071-z

Zahou, X., Sun, H. G., Zhou, C. Y., and Zhang, Y. (2015). Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 22, 105–111. doi: 10.1016/j.cgt.2015.07.030

Zhang, Y., and Cozzi, P. J. (2010). Angiogenesis as a strategic target for prostate cancer therapy. Med. Res. Rev. 30, 23–66. doi: 10.1002/med.20161

Zhao, Z. H., Xiong, X. G., and Xiong, X. G. (2020). Parabacteroides distasonis is a potential key dysbiotic biomarker for IBD patients. J. Clin. Microbiol. 58, 1999–2003. doi: 10.1128/JCM.00168-20

Zhou, Z., Gao, L. F., Liu, H., Guo, C., et al. (2015). Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 22, 105–111. doi: 10.1016/j.cgt.2015.07.030

Zhu, X. T., Gao, L. F., Liu, H., Guo, C., et al. (2015). Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 22, 105–111. doi: 10.1016/j.cgt.2015.07.030

Zhu, X. T., Gao, L. F., Liu, H., Guo, C., et al. (2015). Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 22, 105–111. doi: 10.1016/j.cgt.2015.07.030
study, 1997 to 2015. *Inflamm. Bowel Dis.* 27, 1795–1803. doi: 10.1093/ibd/izaa340

Xu, Y. F., Zhu, L. P., Hu, B., Fu, G. F., Zhang, H. Y., Wang, J. J., et al. (2007). A new expression plasmid in *Bifidobacterium longum* as a delivery system of endostatin for cancer gene therapy. *Cancer Gene Ther.* 14, 151–157. doi: 10.1038/sj.cgt.7701003

Yazawa, K., Fujimori, M., Amano, J., Kano, Y., and Taniguchi, S. (2000). *Bifidobacterium longum* as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. *Cancer Gene Ther.* 7, 269–274. doi: 10.1038/sj.cgt.7700122

Zhao, J., Gao, W., Cai, X., Xu, J., Zou, D., Li, Z., et al. (2019). Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease. *Theranostics* 9, 2843–2855. doi: 10.7150/thno.33727

Zhou, Y., Xu, Z. Z., He, Y., Yang, Y., Liu, L., Lin, Q., et al. (2018). Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. *mSystems* 3, doi: 10.1128/mSystems.00188–17

Zhuang, H. Q., and Yuan, Z. Y. (2009). Process in the mechanisms of endostatin combined with radiotherapy. *Cancer Lett.* 282, 9–13. doi: 10.1016/j.canlet.2008.12.008

**Conflict of Interest:** Z-CH was director of Jiangsu Target Pharma Laboratories Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Bi, Cui, Yao, Chang, Wang, Zhang, Xu, Zhuang and Hua. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.